Clinical Trial Update: An Open-label Extension Study of UCB0942 in Adult Patients With Highly Drug-resistant Focal Epilepsy [Phase 2]

View source ↗

Summary

Open-label extension study of UCB0942 in adults with highly drug-resistant focal epilepsy has been terminated; results posted in 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Focal Epilepsy
• Highly Drug-resistant Focal Epilepsy

Drugs mentioned

• UCB0942

Snippet

Sponsor: UCB Biopharma SRL | Conditions: Highly Drug-resistant Focal Epilepsy | Phase 2 | Status: TERMINATED | Results posted: 2022-01-31